Home › Studies › PRJNA806510
PRJNA806510 SRP359574

Gut microbiota and metformin failure in T2DM, Zhengzhou

Study of Gut Microbiota Mediated Metformin Monotherapy Failure in Type 2 Diabetes Mellitus

50 faecal samples from adult type 2 diabetes mellitus patients in Zhengzhou, China, in a prospective intervention study examining gut microbiota and metformin monotherapy drug therapy response. machine-written summary

72 samples · 72 runs · CN · Adult · 2025 · 10.58 Gbp / sample

Sources
✓Sequence archive 373○Abstract / description✓Full text 124○Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive373 sample values (age, collection date, country, health condition, health condition detail, intervention, latitude, location locality)
○ Abstract / descriptionread; no usable statement
✓ Full text124 sample values (health condition, health condition detail) · PMC12145038
○ Supplementary tablesfiles read; no table could be matched to the samples
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

Non-antibiotic pharmaceutical given as the study intervention (metformin design observational_with_procedure · population type2_diabetes · Metformin monotherapy in newly diagnosed T2DM patients

“newly diagnosed type 2 diabetes mellitus (T2DM) patients treated with metformin monotherapy” — abstract:40487637 (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 sampling locations · 1 country
Age
adult72
Condition
type2_diabetes72
Sex
female5
male5
Country
CN72
Body site
primary72
Collected 2019–2020
2019: 6 samples2020: 4 samples20192020
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)all projects, 1–3 Gbp: 124,983 samples (22 %)all projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 8 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 64 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 10.58 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinal

36 of 36 people sampled more than once (72 samples; median 2, up to 2 per person) · follow-up median 3 mo (max 3 mo) · median interval between samples 3 mo (time from visit codes mapped to the stated schedule). Schedule stated by the source: “Monthly follow-up visits; stool sampled before and after metformin monotherapy treatment” (time origin: intervention_start).

C107C107: day 0C107: day 91S4S4: day 0S4: day 91S46S46: day 0S46: day 910 d23 d46 d2 mo3 mo

Each row is one person (3 shown of 36); dots are samples at days since that person's first sample.

How longitudinal and relatedness information is derived

Community composition
Megamonas 11.9%Phocaeicola 11.0%Bacteroides 8.5%Bifidobacterium 8.0%Roseburia 7.1%Faecalibacterium 4.7%Prevotella 4.4%Blautia_A 4.3%Escherichia 2.4%Ruminococcoides 1.7%Fusicatenibacter 1.7%Mediterraneibacter 1.6%not assigned to a genus 2.5%other genera 30.2%

Genera, mean relative abundance over 44 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category72 100%
country72 100%72
health_condition72 100%1062
subject_id72 100%72
health_condition_detail72 100%1062
detailed_location50 69%
intervention50 69%50
location_locality50 69%50
timepoint_label50 69%50
age_at_collection_days10 14%10
collection_date10 14%10
latitude10 14%10
longitude10 14%10
sex10 14%10
location_region9 12%9
Papers (1)
  • A critical role for <i>Phocaeicola vulgatus</i> in negatively impacting metformin response in diabetes. 2025 PMID 40487637 PMC12145038 own_data
Details
Archive description

In this study, we designed a prospective clinical trial to examine metformin monotherapy failure patients pertinent to gut microbiota.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.

  • host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
  • body site study.title · “Study of Gut Microbiota Mediated Metformin”
  • body site study.description · “patients pertinent to gut microbiota.”
  • life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN37155418age_at_collection_days17897.2R10.70sample.attr.host_age49
SAMN37155418collection_date2019-05R10.90biosample.attribute:collection_date2019-05
SAMN25888864countryCNR10.90sample.attr.geo_loc_nameChina:Zhengzhou
SAMN37155418health_conditiontype2_diabetesR10.90biosample_attrType 2 Diabetes Mellitus
SAMN25888864health_conditiontype2_diabetesR30.70paper.fulltext.methodsChinese Han patients with naïve T2DM were recruited
SAMN37155418health_condition_detailType 2 Diabetes MellitusR10.90sample.attr.host_diseaseType 2 Diabetes Mellitus
SAMN25888864health_condition_detailnewly diagnosed type 2 diabetes mellitus treated with metformin monotherapyR30.70paper.fulltext.methodsChinese Han patients with naïve T2DM were recruited
SAMN25888864interventionno_interventionR10.70sample.name_rule:titleNRBM
SAMN37155418interventionno_interventionR10.85biosample.attribute:chem_administrationchem_administration: NO
SAMN37155418latitude34.7600R10.90biosample.attribute:lat_lon34.76 N 113.62 E
SAMN25888864location_localityZhengzhouR10.85biosample.attribute:geo_loc_nameChina:Zhengzhou
SAMN37155418location_regionHenan ShengR10.60biosample.attribute:lat_lon34.76 N 113.62 E
SAMN37155418longitude113.6200R10.90biosample.attribute:lat_lon34.76 N 113.62 E
SAMN37155418sexmaleR10.90sample.attr.host_sexmale
SAMN25888864subject_idC49R10.70sample.name_rule:source_material_id160468G_C49_1
SAMN25888865subject_idF2R10.70sample.name_rule:library_name160468G_F2_1
SAMN37155418subject_idS4R10.85biosample.attribute:isolateisolate: S4
SAMN25888864timepoint_label1R10.70sample.name_rule:source_material_id160468G_C49_1
SAMN37155418timepoint_labelthe non-responder (before metformin treatment)R10.85biosample.attribute:DESCRIPTIONDESCRIPTION: the non-responder (before metformin treatment)
Sequencing

72 runs over 72 samples · mean 10.81 Gbp per run (median 10.58 Gbp, total 778.22 Gbp; 72 runs with a base count) · layout PAIRED 72 · platform ILLUMINA 72 · models Illumina NovaSeq 6000 (72) · 89% of runs with a Sandpiper profile · first public 2025-01-29 – 2025-05-16

Authors (17)

Chen M first · Peng Y · Hu Y · Kang Z · Chen T · Zhang Y · Chen X · Li Q · Yuan Z · Wu Y · Xu H · Zhou G · Liu T · Zhou H · Yuan C · Huang W · Zhang W last

Downloads

PRJNA806510.csv.gz (3.2 KB) · parquet (75.2 KB) — all 72 samples, every field with route and confidence · PRJNA806510_determinations.csv.gz (5.3 KB) — 497 evidence rows

Samples (72 · every field this project has values for · hover a cell for its source)
Loading the sample table…